99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule

@article{Engfeldt200799mTcchelatorET,
  title={99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule},
  author={Torun Engfeldt and Thuy A. Tran and Anna Orlova and Charles Widstr{\"o}m and Joachim Feldwisch and Lars Bertil Abrahms{\'e}n and A. Wennborg and Amelie Eriksson Karlstr{\"o}m and Vladimir Tolmachev},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2007},
  volume={34},
  pages={1843-1853}
}
Monitoring HER2 expression is crucial for selection of breast cancer patients amenable to HER2-targeting therapy. The Affibody molecule ZHER2:342 binds to HER2 with picomolar affinity and enables specific imaging of HER2 expression. Previously, ZHER2:342 with the additional N-terminal mercaptoacetyl-glycyl-glycyl-glycyl (maGGG) sequence was labelled with 99mTc and demonstrated specific targeting of HER2-expressing xenografts. However, hepatobiliary excretion caused high radioactivity… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Clinical and preclinical application of HER2-specific affibody molecules for diagnosis of recurrent HER2 positive breast cancer by SPECT or PET/CT

  • J Feldwisch, A Orlova, V Tolmachev, R. Baum
  • Molecular Imaging
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…